Luyan Pharma Statistics

Total Valuation

Luyan Pharma has a market cap or net worth of CNY 3.26 billion. The enterprise value is 7.96 billion.

Market Cap	3.26B
Enterprise Value	7.96B

Important Dates

The next estimated earnings date is Monday, August 18, 2025.

Earnings Date	Aug 18, 2025
Ex-Dividend Date	Jul 4, 2024

Share Statistics

Luyan Pharma has 388.52 million shares outstanding. The number of shares has increased by 1.39% in one year.

Current Share Class	388.52M
Shares Outstanding	388.52M
Shares Change (YoY)	+1.39%
Shares Change (QoQ)	+3.27%
Owned by Insiders (%)	3.68%
Owned by Institutions (%)	3.34%
Float	231.73M

Valuation Ratios

The trailing PE ratio is 9.86.

PE Ratio	9.86
Forward PE	n/a
PS Ratio	0.16
PB Ratio	1.00
P/TBV Ratio	1.26
P/FCF Ratio	10.94
P/OCF Ratio	5.41
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.95, with an EV/FCF ratio of 26.73.

EV / Earnings	23.89
EV / Sales	0.39
EV / EBITDA	9.95
EV / EBIT	11.90
EV / FCF	26.73

Financial Position

The company has a current ratio of 1.15, with a Debt / Equity ratio of 1.57.

Current Ratio	1.15
Quick Ratio	0.80
Debt / Equity	1.57
Debt / EBITDA	6.42
Debt / FCF	17.24
Interest Coverage	3.28

Financial Efficiency

Return on equity (ROE) is 10.59% and return on invested capital (ROIC) is 5.07%.

Return on Equity (ROE)	10.59%
Return on Assets (ROA)	3.39%
Return on Invested Capital (ROIC)	5.07%
Return on Capital Employed (ROCE)	16.34%
Revenue Per Employee	3.66M
Profits Per Employee	59,477
Employee Count	5,602
Asset Turnover	1.66
Inventory Turnover	7.38

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -3.68% in the last 52 weeks. The beta is 0.45, so Luyan Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.45
52-Week Price Change	-3.68%
50-Day Moving Average	8.15
200-Day Moving Average	8.18
Relative Strength Index (RSI)	64.00
Average Volume (20 Days)	4,205,006

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Luyan Pharma had revenue of CNY 20.51 billion and earned 333.19 million in profits. Earnings per share was 0.85.

Revenue	20.51B
Gross Profit	1.51B
Operating Income	668.69M
Pretax Income	440.28M
Net Income	333.19M
EBITDA	737.22M
EBIT	668.69M
Earnings Per Share (EPS)	0.85

Full Income Statement

Balance Sheet

The company has 457.88 million in cash and 5.13 billion in debt, giving a net cash position of -4.67 billion or -12.03 per share.

Cash & Cash Equivalents	457.88M
Total Debt	5.13B
Net Cash	-4.67B
Net Cash Per Share	-12.03
Equity (Book Value)	3.26B
Book Value Per Share	8.32
Working Capital	1.30B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 602.29 million and capital expenditures -304.55 million, giving a free cash flow of 297.74 million.

Operating Cash Flow	602.29M
Capital Expenditures	-304.55M
Free Cash Flow	297.74M
FCF Per Share	0.77

Full Cash Flow Statement

Margins

Gross margin is 7.35%, with operating and profit margins of 3.26% and 1.62%.

Gross Margin	7.35%
Operating Margin	3.26%
Pretax Margin	2.15%
Profit Margin	1.62%
EBITDA Margin	3.59%
EBIT Margin	3.26%
FCF Margin	1.45%

Dividends & Yields

This stock pays an annual dividend of 0.35, which amounts to a dividend yield of 4.19%.

Dividend Per Share	0.35
Dividend Yield	4.19%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	97.78%
Buyback Yield	-1.39%
Shareholder Yield	2.81%
Earnings Yield	10.23%
FCF Yield	9.14%

Dividend Details

Stock Splits

The last stock split was on May 29, 2019. It was a forward split with a ratio of 1.7.

Last Split Date	May 29, 2019
Split Type	Forward
Split Ratio	1.7

Scores

Luyan Pharma has an Altman Z-Score of 2.37. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.37
Piotroski F-Score	n/a